Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record.

Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

Open access
Ravandi, Farhad, Jorgensen, Jeffrey L., Thomas, Deborah A., O’Brien, Susan, Garris, Rebecca, Faderl, Stefan, Huang, Xuelin, Wen, Sijin, Burger, Jan A., Ferrajoli, Alessandra, Kebriaei, Partow, Champlin, Richard E., Estrov, Zeev, Challagundla, Pramoda, Wang, Sa A., Luthra, Rajyalakshmi, Cortes, Jorge E., Kantarjian, Hagop M.·2013·Blood

Abstract

From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n = 54) or + dasatinib (n = 68). One hundred fifteen (94%) achieved complete remission (CR) including 101 patients who achieved it with only 1 induction course and had at least 1 minimal residual disease (MRD) assessment; 25 patients underwent an allogeneic stem cell transplant in first CR and were excluded, leaving 76 patients as the subject of this report. MRD monitoring by multiparameter flow cytometry (MFC) and real-time quantitative polymerase chain reaction (PCR) was performed at the end of induction and at ∼3-month intervals thereafter. Median age was 54 years (range, 21-84 years). There was no difference in survival by achievement of at least a major molecular response (MMR; BCR-ABL/ABL < 0.1%) at CR (P = .22). Patients achieving MMR at 3, 6, 9, and 12 months had a better survival (P = .02, .04, .05, and .01, respectively). Negative MFC at CR did not predict for improved survival (P = .2). At 3 and 12 months, negative MRD by MFC was associated with improved survival (P = .04 and .001). MRD monitoring by PCR and MFC identifies patients who benefit from treatment intensification in first CR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-11-466482

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 205

Metadata

Authors
Ravandi, F., Jorgensen, J. L., Thomas, D. A., O’Brien, S., Garris, R., Faderl, S., Huang, X., Wen, S., Burger, J. A., Ferrajoli, A., Kebriaei, P., Champlin, R. E., Estrov, Z., Challagundla, P., Wang, S. A., Luthra, R., Cortes, J. E., & Kantarjian, H. M.
Venue
Blood
Published
2013-08-15
Volume
122
Issue
7
Pages
1214-1221
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2124174337
Cited by
205
References
0
FWCI
20.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. https://app.cochat.ai/papers/10.1182/blood-2012-11-466482
The paper
Ravandi, F., Jorgensen, J. L., Thomas, D. A., O’Brien, S., Garris, R., Faderl, S., Huang, X., Wen, S., Burger, J. A., Ferrajoli, A., Kebriaei, P., Champlin, R. E., Estrov, Z., Challagundla, P., Wang, S. A., Luthra, R., Cortes, J. E., & Kantarjian, H. M. (2013). Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. https://doi.org/10.1182/blood-2012-11-466482

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.